ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CNXU
NTRB (37) LAKE (26) AGPU (42) APT (61) ⌘ Pro Terminal →

Conexeu Sciences Inc. (CNXU) — RQD Stock Rating Cockpit

$2.40 -5.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.37

Conexeu Sciences Inc. (CNXU) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $77.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CNXU Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CNXU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Conexeu Sciences Inc. (NASDAQ: CNXU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $2.40 (-5.51% 1D, market cap $77.0M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CNXU compare to NTRB and LAKE in the Health Care sector?
▼

Within the Health Care sector (Industrial Specialties), CNXU carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NTRB (Nutriband Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $76.6M) and LAKE (Lakeland Industries Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -9.5%, cap $87.3M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CNXU?
▼

Per CNXU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0002066836), Conexeu Sciences Inc. generated $3.2M in revenue, $0 in net income, and $0 in free cash flow against $7.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.37 (-1.18%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 66.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510043
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (10)Whales (3)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.7% Base Target
$20 Bull$2 Base$2 Bear
📬 FREE CNXU RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CNXU)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY CNXU SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 66.8% FCF Margin ($2.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
51
Grade C-$3.31-9.7% Next Q
Q2 (-2Q)
48
Grade D$2.99-1.3% Next Q
Q3 (-1Q)
46
Grade D$2.95-18.6% Next Q
Current
43
Grade D-$2.40-6.7% Hist 90D α
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CNXU Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CNXU currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.19) and Max Pain ($2.52) forces dealer call-delta covering toward $19.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNXU• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CNXU Beats Next Quarter EPS Consensus (Jan 29, 2027) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
36.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $2$2.40H: $19
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on CNXU

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (33)

12/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like CNXU
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CNXU)

  • ✓Walkthrough of CNXU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CNXU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -81.64%⚡ TESTING RESISTANCE
2026-11-03O $2.83H $2.83L $2.40C $2.40VOL 518.9K
RES: $2.81SUP: $0.62SMA50: $4.19SMA200: $7.84
$19.94$15.18$10.43$5.68$0.92RES $2.81SUP $0.62$2.402026-05-212026-07-022026-08-132026-09-232026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CNXU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CNXU Butterfly Map → + Track CNXU →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CNXU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CNXU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CNXU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNXU)

Health Care Rank #412 of 1015 ⚔️ NTRB vs CNXU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CNXU vs. NTRB, LAKE, AGPU, APT)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Conexeu Sciences Inc. (CNXU) ranks #412 by composite RQD confidence (43/100, grade D-) and #684 by equity capitalization ($77.0M). Within this direct 5-issuer industry benchmark cohort, APT leads on earnings valuation at 16.2x trailing P/E, while APT leads on capital efficiency and profitability with 6.7% ROIC and 38.1% gross margin. APT currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with CNXU at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CNXU ACTIVE
Conexeu Sciences Inc.
D- 43/100 — — — -5.51% $77.0M Benchmark Subject
NTRB
Nutriband Inc.
D- 37/100 — 27.8% -35.0% +1.75% $76.6M /ntrb-vs-cnxu →
LAKE
Lakeland Industries Inc.
E 26/100 — 32.9% -9.5% +1.82% $87.3M /lake-vs-cnxu →
AGPU
Axe Compute Inc.
D- 42/100 — — -35.0% -4.87% $92.7M /agpu-vs-cnxu →
APT
Alpha Pro Tech Ltd.
C- 61/100 16.2x 38.1% 6.7% +2.22% $55.1M /apt-vs-cnxu →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-10-31 • CIK 0002066836 ↗

In its most recent audited fiscal period (FY2025, filed 2025-10-31), Conexeu Sciences Inc. (CNXU) reported GAAP revenue of $3.2M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, CNXU closed FY2025 with $7.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-10-31 $3.2M $0 — — $7.7M —

3. CNXU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CNXU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Conexeu Sciences Inc. (NASDAQ: CNXU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $2.40 (-5.51% 1D, market cap $77.0M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

How does CNXU compare to NTRB and LAKE in the Health Care sector?

Within the Health Care sector (Industrial Specialties), CNXU carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NTRB (Nutriband Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $76.6M) and LAKE (Lakeland Industries Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -9.5%, cap $87.3M). Among the 5-stock peer group, APT leads on earnings multiple (16.2x) while APT leads on capital efficiency (6.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CNXU?

Per CNXU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-10-31, CIK 0002066836), Conexeu Sciences Inc. generated $3.2M in revenue, $0 in net income, and $0 in free cash flow against $7.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CNXU trading relative to its 50-day, 200-day, and 52-week technical levels?

CNXU last traded at $2.40 (-5.51% on volume of 340,061 shares), positioning the stock -42.72% below its 50-day simple moving average ($4.19) and -69.39% below its 200-day simple moving average ($7.84). Across its 52-week range of $2.43 to $18.79, CNXU sits at the 0.0% percentile with a 14-day RSI of 36.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.10 to $2.70).

Direct Sub-Reports: CNXU RQD Cockpit CNXU 12M Forecast CNXU Earnings & Move CNXU Dividends & DRIP CNXU Insiders & 13F CNXU Whale Options CNXU Profit Sankey CNXU News & Why
ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ SEC XBRL & RQD VERIFIED

CNXU — Conexeu Sciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-10-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Conexeu Sciences Inc. (CNXU) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.40 (-5.51% 1D, market capitalization $77.0M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Conexeu Sciences Inc. (CNXU) is a NASDAQ-listed issuer classified under the Health Care sector and Industrial Specialties industry..1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-10-31), Conexeu Sciences Inc. (CNXU) reported $3.2M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $7.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 43/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.43 – $18.79 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies: — Sector correlations beyond the stated 6.00x net liquidity elasticity and -0.33 Pearson r: — Second-order bottlenecks: — The macro-liquidity signal is the only cross-market linkage in the source data, and its inverse correlation means that a contraction in net liquidity has historically coincided with the stock's tailwind score in this dataset, per the Butterfly graph.

  • Key Question #1: Can CNXU sustain or expand its — operating margin and — ROIC against Industrial Specialties peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.2M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CNXU's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CNXU Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Conexeu Sciences Inc. (CNXU) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CNXU Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CNXU Bull vs. Bear Conversation Board — What's Your Call at $2.40?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CNXU 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CNXU:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $2.97 (+16.9%)
📌 Pinned Debate

Balance sheet holds up (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and an independent director bought 5.6% more stock, while the B

The street is overcomplicating Conexeu Sciences Inc. (CNXU). Balance sheet holds up (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and an independent director bought 5.6% more stock, while the Butterfly liquidity signal scores a macro tailwind of 96/100.. With an RQD score of 43/100 (D-) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $2.74.

EarningsSniper 🐂 BULL

Both sides have a point here — CNXU's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $1.98 (-22.0%)
Spot @ $2.54

Zero reported revenue and operating income in FY 2025, 0% ROIC and FCF yield, and a pending roughly $5 million financing that carries d

Careful chasing CNXU at $2.54. Zero reported revenue and operating income in FY 2025, 0% ROIC and FCF yield, and a pending roughly $5 million financing that carries dilution risk.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.98 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%